此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

2026年9月28日 更新者:Pfizer

A PHASE 1, OPEN-LABEL, RANDOMIZED, 5-PERIOD, 6-SEQUENCE, CROSSOVER STUDY TO COMPARE THE SINGLE-DOSE PHARMACOKINETICS OF ONE IMMEDIATE RELEASE AND TWO MODIFIED-RELEASE FORMULATIONS OF PF-08049820 ADMINISTERED ORALLY UNDER FASTED AND FED CONDITIONS (PART A), AND A FIXED SEQUENCE STUDY TO ASSESS THE EFFECT OF RABEPRAZOLE ON THE PHARMACOKINETICS OF PF-08049820 (PART B), IN HEALTHY ADULTS

The purpose of this study is to learn how different forms of the study medicine called PF-08049820 are absorbed and eliminated in healthy adults. The study will assess whether the study medicine is absorbed differently when taken with or without food. It will also assess absorption when the study medicine is taken with another medicine called rabeprazole. Rabeprazole is an FDA approved medicine that reduces stomach acid.

The study has two parts. In Part A, participants will take three forms of study medicine, one after the other. They will take each form either with or without food for a total of five doses. Each dose will be separated by a few days. Participants will stay in the clinic for about two weeks. They will receive a telephone follow-up call about a month after the last dose.

In Part B, participants will take three forms of study medicine. They will take each one with or without food, and with or without another medicine called rabeprazole. This means they will take a total of six doses of study medicine. Each dose will be separated by a few days. Participants will stay at the clinic for about three weeks, and about a month after their last dose. They will get a follow-up phone call. Part B may or may not be conducted depending on the results from Part A.

The study is seeking participants who:

  1. Are males or females,
  2. Are at least 18 years of age,
  3. Have a body mass index (BMI) 16 to 32 kilograms per meter squared (kg/m2). Have a total body weight of more than 50 kilograms (kg) (110 pounds).

研究概览

研究类型

介入性

注册 (实际的)

24

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Connecticut
      • New Haven、Connecticut、美国、06511
        • Pfizer Clinical Research Unit - New Haven

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Healthy males and females.
  2. At least 18 years of age
  3. Body mass index (BMI) of 16-32 kg/m2; and a total body weight >50kg (110 lb.).

Exclusion Criteria:

  1. Evidence or history of clinically significant medical conditions.
  2. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B or hepatitis C.
  3. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
  4. Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Sequence 5 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

Administered orally

实验性的:Sequence 7 (Optional Part B)

3 different formulations of PF-08049820 administered orally with or without rabeprazole under fasted or fed conditions.

Administered orally

Administered orally

实验性的:Sequence 1 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

Administered orally

实验性的:Sequence 2 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

Administered orally

实验性的:Sequence 3 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

Administered orally

实验性的:Sequence 4 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

Administered orally

实验性的:Sequence 6 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

Administered orally

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
大体时间:Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

Part A: Evaluate the relative bioavailability of different formulations of PF-08049820.

Optional Part B: Estimate the effect of rabeprazole on the PK of different formulations of PF-08049820.

Baseline up to Day 16 for Part A and up to Day 24 for optional Part B
Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit
大体时间:Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

Part A: Evaluate the relative bioavailability of 3 different formulations of PF-08049820.

Optional Part B: Estimate the effect of rabeprazole on the PK of different formulations of PF-08049820.

Baseline up to Day 16 for Part A and up to Day 24 for optional Part B
Maximum observed plasma concentration (Cmax)
大体时间:Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

Part A: Evaluate the relative bioavailability of 3 different formulations of PF-08049820.

Optional Part B: Estimate the effect of rabeprazole on the PK of different formulations of PF-08049820.

Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

次要结果测量

结果测量
措施说明
大体时间
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
大体时间:Baseline up to Day 48 for Part A and up to Day 56 for optional Part B

Part A and optional Part B

Baseline up to Day 48 for Part A and up to Day 56 for optional Part B
Number of Participants With Serious Adverse Events (SAEs)
大体时间:Baseline up to Day 48 for Part A and up to Day 56 for optional Part B

Part A and optional Part B

Baseline up to Day 48 for Part A and up to Day 56 for optional Part B
Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities
大体时间:Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

Part A and optional Part B

Baseline up to Day 16 for Part A and up to Day 24 for optional Part B
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
大体时间:Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

Part A and optional Part B

Baseline up to Day 16 for Part A and up to Day 24 for optional Part B
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings
大体时间:Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

Part A and optional Part B

Baseline up to Day 16 for Part A and up to Day 24 for optional Part B
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
大体时间:Baseline up to Day 16 for Part A

Part A only: Evaluate the food effect on the PK of different formulations of PF-08049820.

Baseline up to Day 16 for Part A
Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit
大体时间:Baseline up to Day 16 for Part A

Part A only: Evaluate the food effect on the PK of different formulations of PF-08049820.

Baseline up to Day 16 for Part A
Maximum observed plasma concentration (Cmax)
大体时间:Baseline up to Day 16 for Part A

Part A only: Evaluate the food effect on the PK of different formulations of PF-08049820.

Baseline up to Day 16 for Part A

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Pfizer CT.gov Call Center、Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月13日

初级完成 (实际的)

2026年8月7日

研究完成 (实际的)

2026年9月1日

研究注册日期

首次提交

2026年5月12日

首先提交符合 QC 标准的

2026年5月12日

首次发布 (实际的)

2026年5月20日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅